Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

JSON

De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J, CORE-ARV-CTC and ProBIO Investigators

JAMA Oncol 5 (7) 1060-1062 [2019-07-01; online 2019-05-03]

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

PubMed 31046065

DOI 10.1001/jamaoncol.2019.0869

Crossref 10.1001/jamaoncol.2019.0869

pmc: PMC6499126
pii: 2732501